First Trust Advisors
CLDX icon

First Trust Advisors’s Celldex Therapeutics CLDX Stock Holding History

First Trust Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Buy
138,682
+70,212
+103% +$2.27M ﹤0.01% 1566
2026
Q1 		$2.17M Buy
68,470
+30,157
+79% +$822K ﹤0.01% 1875
2025
Q4 		$1.04M Buy
38,313
+2,782
+8% +$73.3K ﹤0.01% 2125
2025
Q3 		$919K Buy
+35,531
New +$823K ﹤0.01% 2119
2025
Q1 		– Sell
-18,372
Closed -$464K – 2549
2024
Q4 		$464K Sell
18,372
-19,071
-51% -$518K ﹤0.01% 2274
2024
Q3 		$1.27M Sell
37,443
-40,293
-52% -$1.54M ﹤0.01% 1943
2024
Q2 		$2.88M Buy
77,736
+7,841
+11% +$296K ﹤0.01% 1538
2024
Q1 		$2.93M Buy
69,895
+58,332
+504% +$2.4M ﹤0.01% 1565
2023
Q4 		$459K Buy
+11,563
New +$340K ﹤0.01% 2160
2023
Q2 		– Sell
-53,072
Closed -$1.91M – 2361
2023
Q1 		$1.91M Buy
+53,072
New +$2.29M ﹤0.01% 1701
2022
Q4 		– Sell
-10,399
Closed -$292K – 2443
2022
Q3 		$292K Buy
10,399
+440
+4% +$13.5K ﹤0.01% 2331
2022
Q2 		$268K Sell
9,959
-42,814
-81% -$1.24M ﹤0.01% 2327
2022
Q1 		$1.8M Sell
52,773
-49,010
-48% -$1.57M ﹤0.01% 1813
2021
Q4 		$3.93M Buy
+101,783
New +$4.44M ﹤0.01% 1486
2016
Q2 		– Sell
-182,343
Closed -$10.3M – 2297
2016
Q1 		$10.3M Sell
182,343
-312,618
-63% -$35.2M 0.03% 643
2015
Q4 		$116M Buy
494,961
+174,302
+54% +$38M 0.3% 61
2015
Q3 		$50.7M Buy
320,659
+31,167
+11% +$8.82M 0.15% 145
2015
Q2 		$110M Sell
289,492
-26,304
-8% -$10.4M 0.28% 76
2015
Q1 		$132M Buy
+315,796
New +$113M 0.39% 36

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors's CLDX Position: Q2 2026 in Review

First Trust Advisors increased its Celldex Therapeutics (CLDX) stake by 103% in Q2 2026, buying an estimated $2.27M and bringing the position to 138,682 shares worth $5.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

First Trust Advisors first reported a position in CLDX in Q1 2015 and has held it in 19 quarters since. The position peaked at $132M in Q1 2015. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • First Trust Advisors held 138,682 shares of Celldex Therapeutics worth $5.16M as of Q2 2026.
  • First Trust Advisors bought 70,212 Celldex Therapeutics shares in Q2 2026, an estimated $2.27M.
  • Celldex Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1566 holding.
  • First Trust Advisors first reported a position in Celldex Therapeutics in Q1 2015 and has held it in 19 quarters since.
  • First Trust Advisors's Celldex Therapeutics position peaked at $132M in Q1 2015.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.